Q-omics provides the consensus-scored NCOA3 profile across patient tissues and cancer cell-line models. NCOA3 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, NCOA3 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, NCOA3 protein abundance shows 26,727 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, HNSC, and LSCC as cancer lineages where NCOA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NCOA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NCOA3 survival associations across molecular data types. NCOA3 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (5) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NCOA3 RNA expression–survival associations across cancer types. High NCOA3 expression shows unfavorable associations in MESO, UVM, KIRP, LIHC and KICH, but favorable associations in KIRC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify MESO as the clearest survival context for NCOA3 RNA expression.
This table summarizes NCOA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for NCOA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NCOA3 shows higher tumor expression in HNSC, LIHC, STAD, BLCA, LUSC and BRCA. The HNSC box plot shows higher NCOA3 RNA expression in tumor versus normal tissue (log2 FC = +1.059, t-test p < 0.001).
This table shows molecular features associated with NCOA3 in patient tissues and cancer cell lines. In patient samples, NCOA3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, NCOA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
